Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin’s Lymphoma

由 Kahl, Brad
出版 2008

Follicular lymphoma: are we ready for a risk-adapted approach?

由 Kahl, Brad S.
發表在 Hematology Am Soc Hematol Educ Program (2017)

Current and emerging treatment options for mantle cell lymphoma

由 Fakhri, Bita, Kahl, Brad
發表在 Ther Adv Hematol (2017)

The Role of rituximab for newly diagnosed, refractory or relapsed aggressive B‐cell lymphoma in adult patients

由 Fitzmaurice, Christina, Zinke, Richard, Heraly, Bradley, Kahl, Brad
發表在 Cochrane Database Syst Rev (2016)

Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis

由 Abouraya, Mahmoud, Sacco, James C, Kahl, Brad S, Trepanier, Lauren A
出版 2011

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

由 Yang, David T, Young, Ken H, Kahl, Brad S, Markovina, Stephanie, Miyamoto, Shigeki
出版 2008

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

由 PETRICH, ADAM, KAHL, BRAD, BAILEY, HOWARD, KIM, KYUNGMANN, TURMAN, NANCY, JUCKETT, MARK
出版 2008

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

由 Goy, André, Hernandez-Ilzaliturri, Francisco J., Kahl, Brad, Ford, Peggy, Protomastro, Ewelina, Berger, Mark
發表在 Leuk Lymphoma (2014)

Use of Tissue Microarray and Automated Quantitative Analysis For Screening and Validation of Potential Biomarkers in Mantle Cell Lymphoma

由 Yang, David T., Quann, Philip J., Petrich, Adam M., Leith, Catherine P., Young, Ken H., Kahl, Brad S.
出版 2011

Microscale functional cytomics for studying hematologic cancers

由 Young, Edmond W. K., Pak, Chorom, Kahl, Brad S., Yang, David T., Callander, Natalie S., Miyamoto, Shigeki, Beebe, David J.
出版 2012

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

由 Thapa, Bicky, Caimi, Paolo F., Ardeshna, Kirit M., Solh, Melhem, Carlo-Stella, Carmelo, Kahl, Brad S., Hamadani, Mehdi
發表在 Blood Adv (2020)

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

由 Treon, Steven P., Soumerai, Jacob D., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Kahl, Brad, Boxer, Michael
出版 2011

Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma

由 Chang, Julie E., Juckett, Mark B., Callander, Natalie S., Kahl, Brad S., Gangnon, Ronald E., Mitchell, Teri L., Longo, Walter L.
出版 2008

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

由 Advani, Ranjana H., Hong, Fangxin, Horning, Sandra J., Kahl, Brad S., Manola, Judith, Swinnen, Lode J., Habermann, Thomas M., Ganjoo, Kristen
出版 2011

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 + indolent NHL: Correlation between clinical responses and AUC pharmac...

由 Casulo, Carla, Vose, Julie M., Ho, William Y., Kahl, Brad, Brunvand, Mark, Goy, Andre, Kasamon, Yvette, Cheson, Bruce, Friedberg, Jonathan W.
發表在 Clin Immunol (2014)

Autologous vs. Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response or...

由 Tomblyn, Marcie R., Ewell, Marian, Bredeson, Christopher, Kahl, Brad S., Goodman, Stacey A., Horowitz, Mary M., Vose, Julie M., Negrin, Robert S., Laport, Ginna G.
出版 2010

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

由 Greenwald, Daniel R, Li, Hailun, Luger, Selina M, Go, Ronald S, King, David, Patel, Taral, Gascoyne, Randy D, Kolesar, Jill, Kahl, Brad S, Horning, Sandra
出版 2013

Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

由 Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
出版 2013

A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402

由 Witzig, Thomas E., Hong, Fangxin, Micallef, Ivana N., Gascoyne, Randy D., Dogan, Ahmet, Wagner, Henry, Kahl, Brad S., Advani, Ranjana H., Horning, Sandra J.
發表在 Br J Haematol (2015)

Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma

由 Kenkre, Vaishalee P., Hong, Fangxin, Cerhan, James R., Lewis, Marcia, Sullivan, Leslie, Williams, Michael E., Gascoyne, Randy D., Horning, Sandra J., Kahl, Brad S.
發表在 Clin Cancer Res (2015)